Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. [electronic resource]
Producer: 20070510Description: 1570-5 p. digitalISSN:- 1527-7755
- Aged
- Aged, 80 and over
- Ambulatory Care
- Boronic Acids -- adverse effects
- Bortezomib
- Canada
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Infusions, Intravenous
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- diagnosis
- Probability
- Protease Inhibitors -- adverse effects
- Pyrazines -- adverse effects
- Risk Assessment
- Salvage Therapy
- Severity of Illness Index
- Survival Rate
- Treatment Outcome
- Waldenstrom Macroglobulinemia -- diagnosis
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.